College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
School of Pharmaceutical Sciences and Innovative Drug Research Centre, Chongqing University, Chongqing 401331, China.
Curr Drug Targets. 2020;21(1):34-54. doi: 10.2174/1389450120666190821160207.
Due to its prevalence and negative impacts on both the economy and society, the diabetes mellitus (DM) has emerged as a worldwide concern. In light of this, the label-free quantification (LFQ) proteomics and diabetic marker selection methods have been applied to elucidate the underlying mechanisms associated with insulin resistance, explore novel protein biomarkers, and discover innovative therapeutic protein targets.
The purpose of this manuscript is to review and analyze the recent computational advances and development of label-free quantification and diabetic marker selection in diabetes proteomics.
Web of Science database, PubMed database and Google Scholar were utilized for searching label-free quantification, computational advances, feature selection and diabetes proteomics.
In this study, we systematically review the computational advances of label-free quantification and diabetic marker selection methods which were applied to get the understanding of DM pathological mechanisms. Firstly, different popular quantification measurements and proteomic quantification software tools which have been applied to the diabetes studies are comprehensively discussed. Secondly, a number of popular manipulation methods including transformation, pretreatment (centering, scaling, and normalization), missing value imputation methods and a variety of popular feature selection techniques applied to diabetes proteomic data are overviewed with objective evaluation on their advantages and disadvantages. Finally, the guidelines for the efficient use of the computationbased LFQ technology and feature selection methods in diabetes proteomics are proposed.
In summary, this review provides guidelines for researchers who will engage in proteomics biomarker discovery and by properly applying these proteomic computational advances, more reliable therapeutic targets will be found in the field of diabetes mellitus.
由于糖尿病(DM)的普遍性及其对经济和社会的负面影响,它已成为全球关注的焦点。有鉴于此,无标记定量(LFQ)蛋白质组学和糖尿病标志物选择方法已被应用于阐明与胰岛素抵抗相关的潜在机制、探索新的蛋白质生物标志物,并发现创新的治疗性蛋白质靶标。
本文旨在综述和分析糖尿病蛋白质组学中无标记定量和糖尿病标志物选择的最新计算进展。
利用 Web of Science 数据库、PubMed 数据库和 Google Scholar 搜索无标记定量、计算进展、特征选择和糖尿病蛋白质组学。
在这项研究中,我们系统地回顾了无标记定量和糖尿病标志物选择方法的计算进展,这些方法被应用于深入了解 DM 的病理机制。首先,全面讨论了已应用于糖尿病研究的各种流行的定量测量和蛋白质组学定量软件工具。其次,综述了一些流行的操作方法,包括转换、预处理(中心化、缩放和平滑)、缺失值插补方法和各种流行的特征选择技术在糖尿病蛋白质组学数据中的应用,并对它们的优缺点进行了客观评价。最后,提出了在糖尿病蛋白质组学中有效使用基于计算的 LFQ 技术和特征选择方法的指南。
总之,本综述为从事蛋白质组学生物标志物发现的研究人员提供了指导,通过正确应用这些蛋白质组学计算进展,将在糖尿病领域发现更可靠的治疗靶点。